

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

These amendments introduce no new matter and support for the amendment is replete throughout the specification and claims as originally filed. These amendments are made without prejudice and are not to be construed as abandonment of the previously claimed subject matter, or agreement with any objection or rejection of record.

Listing of Claims:

Cancel claims 21, 23, and 26 without prejudice, add claims 31-36, and amend the claims as shown below.

1-18. **(Canceled)**

19. **(Currently Amended)** A purified monoclonal [An] antibody, or epitope-binding fragment thereof, which binds to a gp120 epitope bound by [has the characteristics of a] monoclonal antibody 5B3, [selected from the group consisting of 6E10, 13H8, and 6D8] produced by a hybridoma [hybridomas] with ATCC accession number CRL 10515 [numbers CRL 10514, CRL 10510, and CRL 10513, respectively], wherein said antibody or fragment thereof blocks CD4/gp120 binding and reduces reverse transcriptase activity *in vitro*.

20. **(Currently Amended)** A monoclonal antibody, selected from the group consisting of monoclonal antibodies 5B3, [5B6, 5C2, 6D8,] 6E10, [7F11, 7G11, 9E3, 10C1,] and 13H8, produced by hybridomas with ATCC accession nos. CLR 10515, CLR 10514, and CLR 10510, respectively [14F12, AND 15G7, which is covalently bound to a detectable marker or a water insoluble matrix].

21. **(Canceled)** A composition suitable for administration to a patient, said composition comprising a monoclonal antibody selected from the group consisting of monoclonal antibodies 5B3, 5B6, 5C2, 6D8, 6E10, 7F11, 7G11, 9E3, 10C1, 13H8, 14F12, AND 15G7, in a sterile pharmaceutically acceptable vehicle.

22. **(Currently Amended)** The monoclonal antibody [composition] of claim 20 [21], wherein said monoclonal antibody is conjugated to a toxin.

23. **(Canceled)** A method comprising administering a therapeutically acceptable dose of the composition of claim 21 to a patient having or at risk of having HIV infection.

24. **(Canceled)**

25. **(Canceled)**

26. **(Canceled)** The antibody or epitope-binding fragment thereof of claim 19 that is monoclonal.

27. **(Currently Amended)** The purified antibody or epitope-binding fragment thereof of claim 19 that is covalently bound to a detectable marker or a water insoluble matrix.

28. **(Currently Amended)** The purified antibody or epitope-binding fragment thereof of claim 19 [26, selected from the group consisting of] that comprises monoclonal antibody 5B3, produced by a hybridoma with ATCC accession number 10515 [antibodies 6E10, 13H8, and 6D8].

29. **(Currently Amended)** A hybridoma or cell culture comprising an antibody, or epitope-binding fragment thereof, which binds to a gp120 epitope bound by [has the characteristics of a] monoclonal antibody 5B3, [selected from the group consisting of 6E10, 13H8, and 6D8] produced by a hybridoma [hybridomas] with ATCC accession number 10515 [numbers CRL 10514, CRL 10510, and CRL 10513, respectively], wherein said antibody or fragment thereof blocks CD4/gp120 binding and reduces reverse transcriptase activity *in vitro*.

30. **(Currently Amended)** A hybridoma [of claim 29] selected from the group consisting of hybridomas with ATCC accession numbers CRL 10515, CRL 10514, CRL and 10510 [, and CRL 10513].

31. **(New)** The monoclonal antibody of claim 20, wherein said monoclonal antibody is covalently bound to a detectable marker or a water insoluble matrix.

32. **(New)** The purified antibody or epitope-binding fragment thereof of claim 19 that is conjugated to a toxin.

33. **(New)** The monoclonal antibody of claim 20, wherein said monoclonal antibody comprises monoclonal antibody 6E10, produced by a hybridoma with ATCC accession number 10514.

34. **(New)** The monoclonal antibody of claim 20, wherein said monoclonal antibody comprises monoclonal antibody 13H8, produced by a hybridoma with ATCC accession number 10510.

35. **(New)** The hybridoma of claim 30, wherein the hybridoma has ATCC accession no. 10514.

36. **(New)** The hybridoma of claim 30, wherein the hybridoma has ATCC accession no. 10510.

37. **(New)** A monoclonal antibody, selected from the group consisting of monoclonal antibodies 10D8, 10F6 and 11G5, produced by hybridomas with ATCC accession nos. CLR 10513, CLR 10512, and CLR 10511, respectively.

38. **(New)** The monoclonal antibody of claim 37, wherein said monoclonal antibody is conjugated to a toxin.

39. **(New)** The monoclonal antibody of claim 37, wherein said monoclonal antibody is covalently bound to a detectable marker or a water insoluble matrix.

40. **(New)** A hybridoma selected from the group consisting of hybridomas with ATCC accession numbers CRL 10513, CRL 10512, CRL and 10511.